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abstractBACKGROUND: This study in 11- to 15-year-old boys and girls compared the immunogenicity and
safety of GARDASIL 9 (9-valent human papillomavirus [9vHPV] vaccine) administered either
concomitantly or nonconcomitantly with 2 vaccines routinely administered in this age group
(Menactra [MCV4; Neisseria meningitidis serotypes A/C/Y/W-135] or Adacel [Tdap;
diphtheria/tetanus/acellular pertussis]).
METHODS: Participants received 9vHPV vaccine at day 1 and months 2 and 6; the concomitant
group (n = 621) received MCV4/Tdap concomitantly with 9vHPV vaccine at day 1; the
nonconcomitant group (n = 620) received MCV4/Tdap at month 1. Antibodies to HPV-, MCV4-,
and Tdap-relevant antigens were determined. Injection-site and systemic adverse events (AEs)
were monitored for 15 days after any vaccination; serious AEs were monitored throughout the
study.
RESULTS: The geometric mean titers for all HPV types in 9vHPV vaccine 4 weeks after dose 3,
proportion of subjects with a fourfold rise or greater in titers for 4 N meningitidis serotypes
4 weeks after injection with MCV4, proportion of subjects with antibody titers to diphtheria and
tetanus $0.1 IU/mL, and geometric mean titers for pertussis antigens 4 weeks after injection
with Tdap were all noninferior in the concomitant group compared with the nonconcomitant
group. Injection-site swelling occurred more frequently in the concomitant group. There were
no vaccine-related serious AEs.
CONCLUSIONS: Concomitant administration of 9vHPV vaccine with MCV4/Tdap was generally
well tolerated and did not interfere with the antibody response to any of these vaccines.
This strategy would minimize the number of visits required to deliver each vaccine
individually.
WHAT’S KNOWN ON THIS SUBJECT: Previous
studies have shown that concomitant
administration of the quadrivalent human
papillomavirus vaccine with MCV4 and Tdap was
generally well tolerated and did not interfere with
the immune responses to the respective vaccines.
WHAT THIS STUDY ADDS: Concomitant
administration of the novel 9-valent human
papillomavirus vaccine with MCV4 and Tdap, 2
vaccines that are currently recommended for routine
vaccination of adolescents, did not compromise the
safety, tolerability, and immunogenicity of the
individual vaccines.
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A 9-valent (6/11/16/18/31/33/45/
52/58) human papillomavirus (HPV;
9vHPV) vaccine was developed to
cover 7 cancer-causing HPV types
(HPV 16, 18, 31, 33, 45, 52, 58) that
are together responsible for ∼90% of
cervical cancers and HPV-related
vulvar, vaginal, and anal cancers, and
2 HPV types (HPV 6 and 11) that are
responsible for 90% of genital warts.1–5
In clinical studies, the 9vHPV vaccine
prevented persistent infection and
disease due to the HPV vaccine types in
females 16 to 26 years of age6; efﬁcacy
ﬁndings were extended to girls and
boys 9 to 15 years of age based on
noninferior immunogenicity.7 The
9vHPV vaccine was licensed in the
United States in December 2014 under
the name GARDASIL9 (Merck & Co.,
Inc., Kenilworth, NJ).8 In February
2015, the Advisory Committee on
Immunization Practices included
GARDASIL9 in its recommendations for
routine HPV vaccination of boys and
girls at age 11 or 12 years and catchup
vaccination in females 13 to 26 years
and males 13 to 21 years not
vaccinated previously.9 Epidemiologic
studies have demonstrated the
acquisition of HPV soon after sexual
initiation.10 The median age of sexual
debut is in the late teens (15–19
years) in most countries.11 Thus,
preadolescent boys and girls #15
years of age represent the ideal HPV
vaccination population.
Most vaccine schedules worldwide
rely on the concomitant
administration of vaccines to improve
the adherence to vaccination and to
lower the cost of the programs, both
in childhood and in adolescent
vaccination. Because adolescents
and adults need to maintain the
protection given by several childhood
vaccines, such as diphtheria, tetanus,
and whooping cough, and need
to be protected against Neisseria
meningitidis before exposure to new
populations such as those in high
schools, college, or military service,
etc, a booster dose of the diphtheria,
tetanus, and acellular pertussis
vaccines and routine vaccination for
meningococcal serogroups A/C/Y/
W-135 are recommended for
adolescents in several countries.12–14
A logical step was to include the
9vHPV vaccine in those already-
established programs.
This study in boys and girls 11 to 15
years of age was designed to evaluate
the immunogenicity and safety of the
concomitant administration of a ﬁrst
dose of the 9vHPV vaccine with
MCV4 (Menactra [meningococcal
polysaccharide conjugate serogroups
A/C/Y/W-135, Sanoﬁ-Pasteur Inc, Lyon
France]) and Tdap (Adacel [tetanus,
diphtheria, acellular pertussis, Sanoﬁ-
Pasteur Inc]), 2 vaccines that are also
recommended by the Advisory
Committee on Immunization
Practices for routine vaccination of
preadolescents and adolescents and
thereby help inform decisions by those
who would be administering these
vaccines together (Merck Protocol
V503-005; NCT00988884).
METHODS
Study Population
Between October 22, 2009, and
February 22, 2011, 1241 healthy boys
and girls aged 11 to 15 who denied
any sexual activity (and who were not
planning on becoming sexually active
through the course of the study) from
41 sites located in Chile (n = 100),
Colombia (n = 140), Mexico (n = 200),
Peru (n = 100), and the United
States (n = 701) participated in the
study. Reasons for exclusion from
the study included pregnancy
(determined by urine or serum
b-human chorionic gonadotropin
testing), known allergy to
any vaccine component,
thrombocytopenia, and
immunosuppression/prior
immunosuppressive therapy or
previous receipt of an HPV vaccine.
Subjects must not have been
immunized against diphtheria, tetanus,
and pertussis in the past 5 years or
received a meningococcal vaccine. The
study was conducted in conformity
with applicable national or local
requirements regarding ethical
committee review, informed consent,
and the protection of the rights and
welfare of human subjects participating
in biomedical research. An external
data monitoring committee assessed
safety ﬁndings throughout the study.
Study Design
This was an open-label, randomized,
multicenter, comparative study.
Subjects were stratiﬁed by gender (1:1
ratio) and randomly assigned to 1 of 2
vaccination groups (concomitant group
[Group A] or nonconcomitant group
[Group B]) in a 1:1 ratio. At day 1,
subjects in Group A received the ﬁrst
dose of 9vHPV vaccine in the deltoid
muscle of the nondominant arm and
MCV4 and Tdap in the deltoid muscle
of the opposite arm. Subjects in Group
B received the ﬁrst dose of the 9vHPV
vaccine on day 1 in the nondominant
arm and MCV4 and Tdap 1 month later
(month 1) in the dominant arm. All
subjects received the second dose of
the 9vHPV vaccine at month 2 and
the third dose at month 6. The
compositions of the 3 vaccines have
been described previously.6,15,16
Blood samples were drawn
immediately before vaccination at day
1, month 1, month 2 (Group B only),
and month 7. Serum collected from
all subjects at day 1 and month 7
underwent analysis of anti-HPV
responses with a competitive Luminex
Immunoassay, performed by PPD
Vaccines and Biologics (Wayne, PA).17
Serum collected at day 1 and month 1
for Group A and month 1 and month 2
for Group B underwent antibody
testing for N meningitidis serogroups
A/C/Y/W-135, diphtheria, tetanus, and
pertussis. N meningitidis serogroups
A/C/Y/W-135 serum bactericidal
antibody assay was performed by the
Health Protection Agency, Manchester
Medical Microbiology Partnership
(Manchester, United Kingdom).
Diphtheria antibodies were measured
by a diphtheria antitoxin cell culture
assay performed by CSL Limited
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(Parkville, Australia) and calibrated
against the First International Standard
for Diphtheria Antitoxin. Tetanus
antibodies were measured by a tetanus
antitoxin enzyme immunoassay
performed by CSL Limited and
calibrated against the First
International Standard for Tetanus
Immunoglobulin. Pertussis antibodies
were measured by an anti–pertussis
toxin (PT) enzyme-linked
immunosorbent assay (ELISA),
anti–ﬁlamentous hemagglutinin (FHA)
ELISA, anti-pertactin (PRN) ELISA, and
anti–ﬁmbriae 2/3 (FIM) ELISA
performed by Michael E. Pichichero
Laboratory, Rochester General Hospital
Research Institute (Rochester, NY). The
anti-PT ELISA, anti-FHA ELISA, and
anti-FIM ELISA were calibrated against
the US Food and Drug Administration
Pertussis reference lot 3, and the
anti-PRN ELISA was calibrated against
the US Food and Drug Administration
Pertussis reference lot 4.
Safety Measurements
All subjects received a vaccination
report card (VRC) at the day 1 and
months 1, 2, and 6 visits. VRCs for all
the subjects were to be completed after
the month-1 visit to provide a common
period of follow-up even though
subjects in the Group A were not
vaccinated at month 1. On the VRC, the
parent/guardian was asked to record
(1) the subject’s oral temperature in
the evening of the day of each study
vaccination and daily for a total of
5 days and (2) injection-site and systemic
adverse events (AEs) for a total of
15 days including the day of vaccination
after each study vaccination. Serious
AEs were collected for the whole
duration of the study regardless of
causality and were followed for
outcome. For all injection-site AEs,
except erythema and swelling, subjects
were instructed by the VRC to estimate
the severity of AEs as mild (awareness
of symptom but easily tolerated),
moderate (discomfort enough to cause
interference with usual activities), or
severe (incapacitating with inability
to work or do usual activity). For
erythema and swelling, subjects were
instructed by the VRC to measure an
injection-site reaction at its greatest
width (“maximum size”) from edge to
edge in maximum units ranging from
0 to .7 inches (17.5 cm) on the VRC,
rounding up to the next unit if in
between 2 units (each unit on the VRC
measured ∼1 inch [2.5 cm]).
Statistical Analysis
Primary immunogenicity analyses were
done “per-protocol”. Subjects in per-
protocol analyses for the 9vHPV vaccine
analyses had to receive all 3 doses of
9vHPV vaccine within acceptable day
ranges and 1 dose of MCV4 and Tdap.
In addition, for per-protocol analysis for
9vHPV vaccine, subjects had to (1) have
at least 1 postdose 3 serology result
within acceptable day ranges; (2) in
analyses for the HPV6 and HPV11
components, be seronegative to both
TABLE 1 Noninferiority Criteria Corresponding to the Primary Hypotheses Related to Immunogenicity
Antigen Paramatera Expected Rates/SDs Noninferiority Margin Power
HPV type 6, 11, 16, 18, 31, 33, 45, 52, 58b GMT s = 1.2 Twofold decrease .99.9%
N meningitidis Serogroup A % with fourfold or greater rise in titer 90% 10 percentage points 99.8%
N meningitidis Serogroup C % with fourfold or greater rise in titer 90% 10 percentage points 99.8%
N meningitidis Serogroup Y % with fourfold or greater rise in titer 80% 10 percentage points 95.1%
N meningitidis Serogroup W-135 % with fourfold or greater rise in titer 95% 10 percentage points .99.9%
Diphtheria % with titer .0.1 IU/mL 95% 10 percentage points .99.9%
Tetanus % with titer .0.1 IU/mL 92% 10 percentage points 99.8%
Pertussis PT GMT s = 1.0 1.5-fold decrease .99.9%
Pertussis FHA GMT s = 0.8 1.5-fold decrease .99.9%
Pertussis PRN GMT s = 1.3 1.5-fold decrease .99.9%
Pertussis FIM GMT s = 1.5 1.5-fold decrease 97.0%
a Noninferiority of anti-HPV GMTs was measured at 4 weeks after dose 3 of 9vHPV vaccine. Noninferiority of N meningitidis serogroups A/C/Y/W-135, diphtheria, tetanus, and pertussis was
measured 4 weeks postvaccination with MCV4 and Tdap.
b Each HPV type is tested separately
TABLE 2 Summary of Subject Characteristics by Vaccination Group at Enrollment
Characteristic Group Aa (Concomitant)
(N = 621)
Group Ba (Nonconcomitant)
(N = 620)
n (%) n (%)
Gender
Male 310 (49.9) 310 (50.0)
Female 311 (50.1) 310 (50.0)
Age (y)
Mean (SD) 12.2 (1.4) 12.1 (1.3)
Median (range) 12.0 (11 to 15) 12.0 (11 to 15)
Region
North America 344 (55.4) 357 (57.6)
Latin America 277 (44.6) 263 (42.4)
Race
American Indian or Alaska Native 60 (9.7) 59 (9.5)
Asian 6 (1.0) 8 (1.3)
Black or African American 38 (6.1) 41 (6.6)
Multiracial 217 (34.9) 217 (35.0)
Native Hawaiian or Other Paciﬁc Islander 2 (0.3) 5 (0.8)
White 298 (48.0) 290 (46.8)
a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and
Tdap on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as above and MCV4 and Tdap at month 1.
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HPV6 and 11 at day 1; (3) in analyses
for the other vaccine HPV types, be
seronegative at day 1 only for the HPV
type being analyzed; and (4) have
no protocol violations that were
considered to affect the immune
responses. For per-protocol analysis for
MCV4 and Tdap, subjects had to (1)
have received MCV4 and Tdap within
acceptable day ranges; (2) have at least
1 serology result after administration of
MCV4 and Tdap within acceptable day
ranges; and (3) have no protocol
violations that were considered to affect
the immune responses.
The primary and secondary end points
for evaluating antibody responses to the
9vHPV vaccine were geometric mean
titers (GMTs) to HPV6/11/16/18/31/
33/45/52/58 and the percentages of
subjects who seroconverted for each
HPV type by 4 weeks after the third
dose of 9vHPV vaccine. Anti-HPV
cutoffs for determining serostatus were
30, 16, 20, 24, 10, 8, 8, 8, and 8 milli-
Merck units/mL for HPV types 6, 11,
16, 18, 31, 33, 45, 52, and 58,
respectively. The primary end points for
evaluating antibody response to MCV4
and Tdap were the proportions of
subjects who achieved acceptable
serological responses to N meningitidis
serogroups A/C/Y/W-135, diphtheria,
and tetanus and GMTs for pertussis
(anti-PT, anti-FHA, anti-PRN, and
anti-FIM) 4 weeks postvaccination
with MCV4 and Tdap.
Noninferiority criteria for each
immunogenicity hypothesis are shown
in Table 1. Noninferiority of anti-HPV
GMTs 4 weeks postdose 3 and pertussis
GMTs 4 weeks postvaccination with
MCV4 and Tdap was based on 1-sided
tests of noninferiority (conducted at the
0.025 signiﬁcance level) comparing
GMTs between Group A and Group B
for each component. An analysis of
variance model (1 for each component)
was used with a response of loge
individual titers and ﬁxed effects for
vaccination group and gender.
Noninferiority of anti-HPV
seroconversion rates and of serologic
responses to N meningitidis serogroups
TABLE 3 Summary of Exclusionsa From the Per-Protocol Immunogenicity Populations for 9vHPV
Vaccine and MCV4 and Tdap
Concomitant
(Group A),b
N = 619
Nonconcomitant
(Group B),b
N = 618
Exclusions for the 9vHPV vaccine
Number randomized who received $1 injection, n 619 618
Number excluded from the per-protocol immunogenicity
analyses, n (%)
HPV6/11 117 (18.9) 104 (16.8)
HPV16 106 (17.1) 88 (14.2)
HPV18 103 (16.6) 83 (13.4)
HPV31 105 (17.0) 82 (13.3)
HPV33 99 (16.0) 81 (13.1)
HPV45 96 (15.5) 79 (12.8)
HPV52 98 (15.8) 80 (12.9)
HPV58 100 (16.2) 81 (13.1)
Reasons for exclusion, n (%)
Did not receive MCV4 or Tdap 0 (0.0) 18 (2.9)
Received incorrect clinical material 0 (0.0) 2 (0.3)
Received nonstudy vaccinationc 6 (1.0) 8 (1.3)
Received immunosuppressives before month 7 0 (0.0) 2 (0.3)
Incorrectly randomized 2 (0.3) 0 (0.0)
History of immune disorder 1 (0.2) 3 (0.5)
Did not complete the 3-dose regimen of 9vHPV vaccine 32 (5.2) 29 (4.7)
Received $1 dose of 9vHPV vaccine outside the
acceptable day range
10 (1.6) 7 (1.1)
Serum sample or results missing at day 1 3 (0.5) 2 (0.3)
Serum sample or results missing at month 7 78 (12.6) 60 (9.7)
Day 1 seropositive,d n (%) n (%)
HPV6/11e 27 (4.4) 31 (5.0)
HPV16 13 (2.1) 16 (2.6)
HPV18 10 (1.6) 8 (1.3)
HPV31 11 (1.8) 5 (0.8)
HPV33 5 (0.8) 4 (0.6)
HPV45 2 (0.3) 2 (0.3)
HPV52 4 (0.6) 3 (0.5)
HPV58 9 (1.5) 5 (0.8)
Exclusions for MCV4 and Tdap
Number randomized who received $1 injection 619 618
Number excluded from the per-protocol immunogenicity
analyses, n (%)
24 (3.9) 52 (8.4)
Reason for exclusion, n (%)
Did not receive MCV4 or Tdap 0 (0.0) 18 (2.9)
Received incorrect clinical material 0 (0.0) 2 (0.3)
Received nonstudy vaccinationc 3 (0.5) 8 (1.3)
Received immunosuppressives before month 7 0 (0.0) 2 (0.3)
Incorrectly randomized 2 (0.3) 0 (0.0)
With history of immune disorder 1 (0.2) 3 (0.5)
Received MCV4 and Tdap outside the acceptable day
range
0 (0.0) 13 (2.1)
Serum sample or results missing at 4 wk postinjection
of Tdap-IPV vaccine
18 (2.9) 31 (5.0)
Received incorrect Tdap dosef 0 (0.0) 1 (0.2)
a A subject may appear in .1 category.
b Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6, and
MCV4 and Tdap on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as with Group A together with
MCV4 and Tdap at month 1.
c Includes (1) any live vaccine received 21 d before or 14 d after study vaccine or (2) any inactivated or recombinant
vaccine received within 14 d of study vaccine.
d Seropositive at day 1 to the relevant HPV types(s) applies to the per protocol population for the relevant HPV type(s) only.
e Because the L1 proteins for HPV6 and HPV11 are 92% homologous at the amino acid level, all participants were required
to be seronegative to both HPV6 and HVP11 to be included in either of the HPV6 and HPV11 per-protocol immunogenicity
populations.
f Excluded from the per protocol immunogenicity population for Tdap; not excluded from the per protocol immunogenicity
population for MCV4.
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A/C/Y/W-135, diphtheria, and tetanus
was tested by 1-sided tests of
noninferiority comparing proportions
between Group A and Group B for each
component. These tests were conducted
based on methods developed by
Miettinen and Nurminen.18 All tests
were conducted at the 0.025
signiﬁcance level. Success in this study
was declared if the primary hypotheses
of noninferiority were demonstrated for
all components of 9vHPV vaccine and at
least 1 of MCV4 and Tdap. With 620
subjects per group (1240 total), this
study had an overall power .99% for
the primary immunogenicity
hypotheses (Table 1).
All subjects who received at least 1
study vaccination and had follow-up
data were included in safety analyses.
AEs were summarized descriptively
as frequencies and percentages by
participant groups.
RESULTS
A total of 1254 subjects residing in Latin
America and North America were
screened for inclusion in this study and
1241 were randomized (621 to Group A
and 620 to Group B). The numbers of
subjects who were randomized,
vaccinated, and completed or
discontinued the study are shown in
Supplemental Figure 1. Both vaccination
groups were comparable with respect to
baseline demographics (Table 2).
Approximately 6.4% (79 of 1241) of
patients were African American, and
1.1% (14/1241) were Asian.
The most common reason for exclusion
from the per-protocol analyses was
having a serum sample or result
missing at 4 weeks postinjection
(Table 3). Few subjects (0.3%–4.7%)
were excluded from the per-protocol
analyses for 9vHPV vaccine because of
testing positive for HPV on Day 1.
Month 7 anti-HPV GMTs against all
HPV types were comparable in Group
A and Group B, with fold differences
(ie, Group A/Group B) ranging from
0.97 for HPV6 and HPV11 to 1.10 for
HPV45 (Table 4). The noninferiority
criteria for the anti-HPV GMT
responses in Group A relative
to Group B were achieved.
Seroconversion rates were 100% for
all HPV types in both groups and
were noninferior in Group A
compared with Group B (Table 5).
At least 75% of subjects achieved
a fourfold or higher rise in titers to
N meningitidis serogroup A in both
Group A and Group B, and at least 89%
of subjects achieved a fourfold or higher
rise in titers to N meningitidis
serogroups C, Y, and W-135 in both
Group A and Group B (Table 6). The
noninferiority criterion was met for all
4 N meningitidis serogroups. More than
99.8% of subjects in both Group A and
Group B achieved a diphtheria and
tetanus titer $0.1 IU/mL at 4 weeks
postvaccination with Tdap. There was
a 0 to 0.2 percentage point difference
(Group A –Group B) in the percentage of
subjects who achieved titers$0.1 IU/mL,
and the noninferiority criteria for
both antigens were met (Table 7).
TABLE 4 Anti-HPV GMTs and Estimated Fold Difference at 4 Weeks After Dose 3 in the HPV Per-
Protocol Populations
Antigen Concomitant (Group A),a
N = 619
Nonconcomitant (Group B),a
N = 618
Estimated Fold
Difference Group A/Group Bb
(95% Conﬁdence Interval)
n Estimated GMT (mMU/mL) n Estimated GMT (mMU/mL)
HPV6 501 2198.7 514 2260.7 0.97 (0.88 to 1.08)
HPV11 502 1495.0 514 1547.2 0.97 (0.87 to 1.07)
HPV16 513 8882.6 530 9027.6 0.98 (0.89 to 1.09)
HPV18 516 2610.4 535 2633.9 0.99 (0.88 to 1.12)
HPV31 514 2439.4 536 2334.3 1.04 (0.93 to 1.17)
HPV33 520 1268.5 537 1276.3 0.99 (0.89 to 1.11)
HPV45 523 947.8 539 863.8 1.10 (0.97 to 1.25)
HPV52 521 1082.7 538 1103.7 0.98 (0.88 to 1.10)
HPV58 519 1532.8 537 1555.1 0.99 (0.88 to 1.10)
mMU, milliMerck units; N, number of subjects randomized to the respective vaccination group who received $1 injection;
n = number of subjects contributing to the analysis.
a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and Tdap
on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as Group A and MCV4 and Tdap at month 1.
b P value for noninferiority ,.001 for all 9 antigens. The noninferiority criterion for GMT end points reported in this table was
deﬁned as statistically less than a twofold decrease in Group A compared with Group B. Noninferiority of GMT in Group A relative
to Group B was demonstrated if the lower limit of the 95% conﬁdence interval for the fold difference was .0.5.
TABLE 5 Seroconversion Rates and Estimated Percent Difference at 4 Weeks After Dose 3 in the
HPV Per-Protocol Populations
Antigen Concomitant
(Group A),a N = 619
Nonconcomitant
(Group B),a N = 618
Estimated Percent Difference
Group A – Group Bb
(95% conﬁdence interval)
m/n Response (%) m/n Response (%)
HPV6 501/501 100 514/514 100 0.0 (–0.8 to 0.7)
HPV11 502/502 100 514/514 100 0.0 (–0.8 to 0.7)
HPV16 513/513 100 530/530 100 0.0 (–0.7 to 0.7)
HPV18 516/516 100 535/535 100 0.0 (–0.7 to 0.7)
HPV31 514/514 100 536/536 100 0.0 (–0.7 to 0.7)
HPV33 520/520 100 537/537 100 0.0 (–0.7 to 0.7)
HPV45 523/523 100 539/539 100 0.0 (–0.7 to 0.7)
HPV52 521/521 100 538/538 100 0.0 (–0.7 to 0.7)
HPV58 519/519 100 537/537 100 0.0 (–0.7 to 0.7)
m = number of subjects with the indicated response; N, number of subjects randomized to the respective vaccination
group who received at least 1 injection; n, number of subjects contributing to the analysis. Seropositive is deﬁned as anti-
HPV serum levels (assessed by competitive Luminex immunoassay) greater or equal to 30, 16, 20, 24, 10, 8, 8, 8, 8
milliMerck units/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and Tdap
on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as Group A and MCV4 and Tdap at month 1.
b P value for noninferiority,.001 for all 9 antigens. The noninferiority criterion for seroconversion end points reported in
this table was deﬁned as statistically,5 percentage points decrease in Group A compared with Group B. Noninferiority of
seroconversion rates in Group A relative to Group B was demonstrated if the lower limit of the 95% conﬁdence interval for
the percentage point difference was greater than –5.
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With respect to pertussis antigens the
per-protocol immunogenicity analysis
also showed that anti-PT, anti-FHA,
anti-PRN, and anti-FIM GMTs were
noninferior in Group A compared
with Group B (Table 8).
Few subjects (∼0.2%) discontinued
because of an AE, and no deaths were
reported (Table 9). Throughout the
study period, 5 subjects (0.8%) in
Group A and 5 subjects (0.8%) in
Group B reported nonfatal serious
AEs; none were vaccine related.
Regarding injection-site AEs, a higher
proportion of subjects in Group A
reported swelling (14.4%) at the
9vHPV vaccination site compared
with Group B (9.4%), and the
difference between the groups was
statistically signiﬁcant (P = .007;
Table 10). Comparable proportions of
subjects reported swelling at MCV4
and Tdap vaccination site in Group A
and Group B (P = .526; Table 10).
Most of the swelling was mild to
moderate in intensity (ie, with
a maximum size ,5 cm) both at the
9vHPV vaccine injection site and the
MCV4 and Tdap injection site. Most
subjects in each group (Group A:
92.3%; Group B: 91.9%) reported
a maximum temperature ,37.8°C
(,100°F) within 5 days of the ﬁrst
vaccination. The proportions with
elevated temperatures ($37.8°C)
within 5 days of the ﬁrst vaccination
were similar between the 2 groups
(risk difference: –0.4; 95% conﬁdence
interval: –3.5 to 2.7). No subject
became pregnant during the study.
DISCUSSION
This study demonstrated that when
the ﬁrst dose of 9vHPV vaccine is
administered concomitantly with MCV4
and Tdap at a separate injection site,
the immune response to all vaccine
components is noninferior to the
immune response achieved when
the 3 vaccines are administered
nonconcomitantly. Speciﬁcally, GMTs
to all 9 vaccine HPV types were
noninferior in Group A compared with
Group B, and all subjects in both
vaccination groups seroconverted after
the third dose of 9vHPV vaccine. Also,
antibody responses to N meningitidis
serogroups A/C/Y/W-135, diphtheria,
tetanus, and pertussis at 4 weeks after
administration of MCV4 and Tdap were
noninferior in Group A compared with
Group B.
Concomitant administration of the ﬁrst
dose of 9vHPV vaccine with MCV4 and
Tdap was generally well tolerated.
The proportion of subjects reporting
injection site AEs postvaccination 1 was
similar in the concomitant vaccination
group (85.3%) and the nonconcomitant
vaccination group (85.1%). Signiﬁcantly
more subjects reported swelling at the
TABLE 6 Estimated Percentage Point Difference in the Per-Protocol Population for MCV4 for Percent of Subjects With Fourfold or Greater Rise in Titers
for N meningitidis Serogroups at 4 Weeks Postvaccination
Concomitant (Group A),a N = 619 Nonconcomitant (Group B),a N = 618 Estimated Percentage Point Difference
Group A – Group B (97.5% CI)
m/n % 97.5% CI m/n % 97.5% CI
Serogroup A 466/590 79.0 (75.0 to 82.6) 425/564 75.4 (71.0 to 79.3) 3.8 (–1.7 to 9.3)b
Serogroup C 548/590 92.9 (90.1 to 95.1) 538/566 95.1 (92.6 to 96.9) 22.1 (–5.4 to 1.1)b
Serogroup W-135 563/589 95.6 (93.3 to 97.3) 553/566 97.7 (95.9 to 98.9) 22.1 (–4.7 to 0.3)b
Serogroup Y 540/590 91.5 (88.6 to 93.9) 506/566 89.4 (86.1 to 92.1) 2.1 (–1.8 to 6.1)b
m = number of subjects with the indicated response; N, number of subjects randomized to the respective vaccination group who received at least 1 injection; n, number of subjects
contributing to the analysis. CI, conﬁdence interval.
a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and Tdap on day 1; Group B (nonconcomitant administration)
received 9vHPV vaccine as above and Tdap-IPV vaccine at month 1.
b P value for noninferiority,.001 for all antigens. The noninferiority criterion for end points reported in this table was deﬁned as statistically ,10 percentage points decrease in Group A
compared with Group B. Noninferiority of percent of subjects with fourfold or greater rise in titers for N meningitidis serogroups in Group A relative to Group B was demonstrated if the
lower limit of the 97.5% CI for the percentage point difference was greater than –10.
TABLE 7 Estimated Percentage Point Difference in the Per-Protocol Population for Tdap for Percent of Subjects With Diphtheria and Tetanus Titers
$0.1 IU/mL at 4 Weeks Postvaccination
Concomitant (Group A),a N = 619 Nonconcomitant (Group B),a N = 618 Estimated Percentage Point Difference
Group A – Group B (97.5% CI)
m/n % 97.5% CI m/n % 97.5% CI
Diphtheria titer $0.1 IU/mL
Day 1 403/593 68.0 (63.5 to 72.2) 391/564 69.3 (64.8 to 73.6)
4 wk postvaccination 595/595 100 (99.3 to 100) 566/566 100 (99.2 to 100) 0.0 (–0.8 to 0.9)b
Tetanus titer $0.1 IU/mL
Day 1 460/573 80.3 (76.3 to 83.9) 450/548 82.1 (78.1 to 85.6)
4 wk postvaccination 593/594 99.8 (98.9 to 100) 562/562 100 (99.2 to 100) 20.2 (–1.2 to 0.7)b
m = number of subjects with the indicated response; N, number of subjects randomized to the respective vaccination group who received at least 1 injection; n, number of subjects
contributing to the analysis. CI, conﬁdence interval.
a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and Tdap on day 1; Group B (nonconcomitant administration)
received 9vHPV vaccine as Group A and Tdap-IPV vaccine at month 1.
b P value for non-inferiority ,0.001 for all antigens. The non-inferiority criterion for endpoints reported in this table was deﬁned as statistically less than 10 percentage points decrease
in Group A compared with Group B. Non-inferiority of percent with titer $ 0.1 IU/mL in Group A relative to Group B was demonstrated if the lower limit of the 97.5% CI for the percentage
point difference was greater than 210.
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9vHPV vaccine injection site after the
ﬁrst vaccination in the concomitant
group. Injection-site swelling at the
9vHPV vaccine injection site was mostly
mild to moderate in intensity. Moreover,
there were few discontinuations due to
an AE. Thus, the ﬁnding of increased
rates of injection-site swelling is likely
to be of minor clinical signiﬁcance. In
another study that investigated
concomitant administration of 9vHPV
vaccine with a diphtheria/tetanus/
pertussis/polio vaccine, more subjects
also reported swelling at the 9vHPV
vaccine injection site in the concomitant
vaccination group.19 This suggests that
the increase in injection-site swelling
may be due to the concomitant
administration of diphtheria/tetanus/
pertussis antigens (rather than
meningococcal antigens) with 9vHPV
vaccine.
The results of this study are similar to
those of a previous study of
concomitant administration of the
quadrivalent HPV (types 6/11/16/
18) vaccine and MCV4 and Tdap,
TABLE 8 Antipertussis GMTs and Estimated Fold Difference at 4 Weeks Postvaccination in the Per-Protocol Population for Tdap
Concomitant (Group A),a N = 619 Nonconcomitant (Group B),a N = 618 Estimated Fold Difference
Group A/Group B (97.5% CI)
n Estimated GMT (ELU/m) 97.5% CI n Estimated GMT (ELU/m) 97.5% CI
Anti-PT
Day 1 594 7.5 (6.8 to 8.2) 564 7.1 (6.5 to 7.8)
4 wk postvaccination 595 28.5 (25.8 to 31.5) 566 35.7 (32.3 to 39.6) 0.80 (0.69 to 0.92)b
Anti-FHA
Day 1 594 33.0 (30.4 to 35.8) 564 32.8 (30.1 to 35.7)
4 wk postvaccination 595 184.1 (171.8 to 197.4) 566 201.4 (187.6 to 216.3) 0.91 (0.83 to 1.01)b
Anti-PRN
Day 1 594 20.9 (19.2 to 22.8) 564 20.4 (18.6 to 22.4)
4 wk postvaccination 595 328.4 (300.6 to 358.8) 566 344.0 (314.2 to 376.7) 0.95 (0.84 to 1.08)b
Anti-FIM
Day 1 594 16.1 (14.3 to 18.2) 564 15.8 (13.9 to 18.1)
4 wk postvaccination 595 653.0 (556.0 to 767.1) 566 681.4 (577.8 to 803.7) 0.96 (0.76 to 1.21)b
N, number of subjects randomized to the respective vaccination group who received at least 1 injection; n, number of subjects contributing to the analysis. CI, conﬁdence interval.
a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and Tdap on day 1; Group B (nonconcomitant administration)
received 9vHPV vaccine as Group A and Tdap-IPV vaccine at month 1.
b P value for noninferiority,.001 for all antigens with the exception of anti-pertussis toxin, where P for noninferiority was .003. The noninferiority criterion for end points reported in this
table was deﬁned as statistically ,1.5-fold decrease in Group A compared with Group B. Noninferiority of GMT in Group A relative to Group B was demonstrated if the lower limit of the
97.5% CI for the fold difference was .0.67.
TABLE 9 AEs Reported Day 1 Through 15 After the Respective Vaccination Visit
Postvaccination 1a Postvaccination 2b Postvaccination 3b
Concomitant
(Group A)c
Nonconcomitant
(Group B) c
Concomitant
(Group A)c
Nonconcomitant
(Group B) c
Concomitant
(Group A)c
Nonconcomitant
(Group B) c
Subjects with follow-up, n 613 611 591 593 583 581
Subjects with $1 AE, n (%) 523 (85.3) 520 (85.1) 307 (51.9) 299 (50.4) 323 (55.4) 307 (52.8)
Injection-site 496 (80.9) 491 (80.4) 276 (46.7) 276 (46.5) 304 (52.1) 281 (48.4)
Systemic 264 (43.1) 259 (42.4) 95 (16.1) 89 (15.0) 86 (14.8) 94 (16.2)
Seriousd 1e (0.2) 1f (0.2) 1g (0.2) 0 (0.0) 1h (0.2) 0 (0.0)
Serious vaccine-related 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinued due to an AE, n (%) 0 (0.0) 1 (0.2) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinued due to death, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
All subjects who received$1 injection and had follow-up data were included in the primary analysis of safety. The number and percent of subjects reporting the following were compared
between Group A and Group B: systemic AEs on days 1 through 15 after any vaccination and the number of subjects reporting clinical serious AEs from days 1 to 15 after any vaccination
or vaccine-related clinical serious AE at any time during the study.
a Postvaccination 1 is deﬁned as the follow-up period for safety after vaccination at day 1 and after vaccination/visit at month 1. These data represent AEs reported for the 2 vaccines combined.
b Because 9vHPV vaccine was the only vaccine administered in a 3-dose regimen, AEs reported postvaccination 2 and 3 would be speciﬁc to 9vHPV vaccination.
c Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and a 0.5-mL dose of MCV4 and Tdap on day 1; Group B (nonconcomitant
administration) received 9vHPV vaccine as Group A and MCV4 and Tdap at month 1. Two subjects randomized into the nonconcomitant group received 9vHPV vaccine at day 1 but did not
receive MCV4 and Tdap at month 1 and are excluded from this table.
d There were 7 additional serious AE reported outside the day 1 to 15 time window. Group A: appendicitis 27 d postdose 2 of 9vHPV vaccine (5-d duration); appendicitis 93 d postdose 2 of 9vHPV vaccine
(4-d duration). Group B: appendicitis 61 d postdose 1 of 9vHPV vaccine (1.3-wk duration); orthostatic hypotension 193 d postdose 1 of 9vHPV vaccine (3-d duration); depression 40-d postdose 2 of 9vHPV
vaccine (3-d duration); dengue fever 47 d postdose 2 of 9vHPV vaccine (1.6-wk duration); bronchitis 127 d postdose 2 of 9vHPV vaccine (6-d duration). Thus, throughout the study period, there were 11
serious non–vaccine-related AEs reported for 10 subjects: 5 subjects (0.8%) in Group A and 5 subjects (0.8%) in Group B (1 subject experienced 2 serious AEs: gastroenteritis and orthostatic hypotension).
All serious AEs were considered not related to any of the 3 study vaccines by the study investigators (investigators were instructed to assign causality to AEs on the basis of exposure, time course, likely
cause, and consistency with the vaccine’s known proﬁle; vaccine-related AEs were those that were determined by the investigator to be possibly, probably, or deﬁnitely vaccine related).
e Seroma 9 d postdose 1 of 9vHPV vaccine (4.3-wk duration).
f Gastroenteritis 6 d postdose 1 of 9vHPV vaccine (2-d duration).
g Affective disorder 1 d postdose 2 of 9vHPV vaccine (1.1-wk duration).
h Testicular torsion 8 d postdose 3 (2-d duration).
PEDIATRICS Volume 136, number 3, September 2015 7
 at Merck & Co Inc on August 3, 2015pediatrics.aappublications.orgDownloaded from 
which showed that concomitant
administration of dose 1 of
quadrivalent HPV vaccine and MCV4
and Tdap was generally well
tolerated and did not interfere with
the antibody response to any of the
vaccine antigens; similar to this study,
increased rates in injection-site
swelling were also noted in the
concomitant vaccination group.20
The primary limitation of this study
was its unblinded nature. As such,
safety assessment could have been
biased toward an overestimation
of AEs being reported in the
concomitant vaccination group
because subjects who are receiving 2
injections on the same day may more
likely report injection-site or systemic
AEs compared with subjects who
receive only 1 injection. Another
limitation of this study is that the
coadministration of Tdap and MCV4
was assessed only with the ﬁrst dose
of HPV vaccine and not with
subsequent doses.
Even though only 1 Tdap vaccine
was assessed in this study, one can
reasonably assume that the results may
be generalizable to other Tdap vaccines.
Differences in antigen and aluminum
dose between diphtheria/tetanus/
pertussis vaccines such as Adacel,
Boostrix-IPV, or Repevax are relatively
modest and therefore expected to have
limited impact on 9vHPV vaccine
immunogenicity. A limited impact on
9vHPV vaccine immunogenicity is
unlikely to have clinical signiﬁcance:
the 9vHPV vaccine efﬁcacy ﬁndings
in young women were extended
to adolescents based on the
demonstration of noninferior anti-HPV
responses7; anti-HPV responses in
adolescents were actually much higher
than in young women. Even if
concomitant administration of
a different diphtheria/tetanus/pertussis
vaccine were associated with a small
decrease in 9vHPV vaccine
immunogenicity, anti-HPV responses
would still be substantially higher than
in young women, and therefore
protection elicited by 9vHPV vaccine
would not be compromised.
When the study was initiated in 2009,
other meningococcal serotype A/C/
Y/W-135 vaccines (Menveo and
Nimenrix) had not yet been licensed.
Although Menactra, Menveo, and
Nimenrix contain similar amounts of
polysaccharide and carrier protein,
they use different carrier proteins;
thus, it is difﬁcult to speculate
whether results obtained in this study
can be extrapolated to other
meningococcal vaccines. Regulatory
guidelines caution against such
extrapolation for conjugated
polysaccharide vaccines.21
This study demonstrates that
concomitant administration of 9vHPV
vaccine and MCV4 and Tdap was
generally well tolerated and the
immune responses to components of
either vaccine were noninferior
compared with nonconcomitant
administration. Providing
vaccinations to adolescents is
challenging because they make
infrequent health care visits.
Concomitant administration would
minimize the number of visits
required to deliver each vaccine
individually and therefore facilitate
adherence to recommended vaccination
regimens. In the United States, coverage
for the ﬁrst dose of HPV vaccine
remains substantially lower (by
∼20–25 percentage points) than
coverage for other vaccines
recommended by the Advisory
Committee on Immunization Practices
for children 11 to 12 years of age.22,23 It
is estimated that coadministration of
HPV vaccine with other vaccines such
as diphtheria, tetanus, pertussis,
meningococcal conjugate, and inﬂuenza
vaccines could increase coverage
for the ﬁrst dose of HPV vaccine
to .90%.24
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ABBREVIATIONS
9vHPV: 9-valent HPV (6/11/16/
18/31/33/45/52/58) L1
virus-like particle vaccine
AEs: adverse events
ELISA: enzyme-linked
immunosorbent assay
FHA: ﬁlamentous hemagglutinin
FIM: ﬁmbriae 2/3
GMT: geometric mean titers
HPV: human papillomavirus
PRN: pertactin
PT: pertussis toxin
VRC: vaccination report card
TABLE 10 Injection-Site AEs Prompted for on the VRC
Concomitant
(Group A)a
Nonconcomitant
(Group B)a
% Difference Group A
vs Group B (95% CI)
P
9vHPV injection site (reported d 1–5 postdose 1)
Subjects contributing to the analysis, n 611 609
Erythema, n (%) 61 (10.0) 54 (8.9) 1.1 (–2.2 to 4.4) .505
Pain, n (%) 356 (58.3) 335 (55.0) 3.3 (–2.3 to 8.8) .251
Swelling, n (%) 88 (14.4) 57 (9.4) 5.0 (1.4 to 8.7) .007
MCV4 and Tdap injection site (reported d 1–5 postvaccination)
Subjects contributing to the analysis, n 611 598
Erythema, n (%) 159 (26.0) 152 (25.4) 0.6 (–4.3 to 5.5) .810
Pain, n (%) 439 (71.8) 406 (67.9) 4.0 (–1.2 to 9.1) .134
Swelling, n (%) 188 (30.8) 174 (29.1) 1.7 (–3.5 to 6.8) .526
All subjects who received $1 injection and had follow-up data were included in the primary analysis of safety. The
number and percent of subjects reporting injection-site AEs were compared between Group A and Group B. Risk
differences, 95% CIs and P values were calculated for injection site AEs between day 1 and day 5 for both groups. CI,
conﬁdence interval.
a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and a
0.5-mL dose of MCV4 and Tdap on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as Group A and
MCV4 and Tdap at month 1. Two subjects randomized into the nonconcomitant group received 9vHPV vaccine at day 1 but
did not did not receive MCV4 and Tdap at month 1 and are excluded from this table.
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